These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12361396)

  • 1. Imidazole inhibitors of cytokine release: probing substituents in the 2 position.
    Laufer SA; Striegel HG; Wagner GK
    J Med Chem; 2002 Oct; 45(21):4695-705. PubMed ID: 12361396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From imidazoles to pyrimidines: new inhibitors of cytokine release.
    Laufer SA; Wagner GK
    J Med Chem; 2002 Jun; 45(13):2733-40. PubMed ID: 12061876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
    Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
    J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.
    Laufer SA; Zimmermann W; Ruff KJ
    J Med Chem; 2004 Dec; 47(25):6311-25. PubMed ID: 15566301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs.
    Laufer S; Greim C; Bertsche T
    Osteoarthritis Cartilage; 2002 Dec; 10(12):961-7. PubMed ID: 12464556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative structure-activity relationship study of benzylsulfanyl imidazoles as cytokine release inhibitors.
    Singh P; Sharma BK
    J Enzyme Inhib Med Chem; 2007 Feb; 22(1):15-21. PubMed ID: 17373542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
    Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
    J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells.
    Leonard M; Ryan MP; Watson AJ; Schramek H; Healy E
    Kidney Int; 1999 Oct; 56(4):1366-77. PubMed ID: 10504489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers.
    Arrighi JF; Rebsamen M; Rousset F; Kindler V; Hauser C
    J Immunol; 2001 Mar; 166(6):3837-45. PubMed ID: 11238627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
    Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
    Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.
    Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL
    J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness.
    Faas MM; Moes H; Fijen JW; Muller Kobold AC; Tulleken JE; Zijlstra JG
    Clin Exp Immunol; 2002 Feb; 127(2):337-43. PubMed ID: 11876759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecular anti-cytokine agents.
    Wagner G; Laufer S
    Med Res Rev; 2006 Jan; 26(1):1-62. PubMed ID: 16283677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle.
    Hallsworth MP; Moir LM; Lai D; Hirst SJ
    Am J Respir Crit Care Med; 2001 Aug; 164(4):688-97. PubMed ID: 11520738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor.
    Westra J; Doornbos-van der Meer B; de Boer P; van Leeuwen MA; van Rijswijk MH; Limburg PC
    Arthritis Res Ther; 2004; 6(4):R384-92. PubMed ID: 15225374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
    Koch P; Laufer S
    J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.
    Newton R; Cambridge L; Hart LA; Stevens DA; Lindsay MA; Barnes PJ
    Br J Pharmacol; 2000 Jul; 130(6):1353-61. PubMed ID: 10903976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
    J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.